Almac Adds Simple Solutions to Bridge the Gap Between Clinical and Commercial Packaging - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Almac Adds Simple Solutions to Bridge the Gap Between Clinical and Commercial Packaging

Source: Company News Release

Addressing client demand to ease the transition between clinical and commercial launch for blister products, Almac, provider in clinical and commercial contract packaging to the global Pharmaceutical and Biotech industries, has added new blistering technology at their US commercial packaging facility in Audubon, PA

The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials. This provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost effective stability packaging.

David Moore, Director of Operations at the Audubon facility explains “Almac are offering seamless services from clinical supply, packaging development / design and stability testing to final commercial pack from its two Pennsylvania sites. Clients can now easily transition from the clinical blister presentation though various development packs, with Almac providing all the associated stability services.”

The addition of a further blister line complements the already impressive array of clinical and commercial packaging capabilities of blistering, bottling, walleting and vial /ampoule labelling available at Almac.

For more information on Almac’s US packaging capabilities, please contact
uspack@almacgroup.com


Almac will be exhibiting at Pharma Packaging & Labeling Philadelphia 26 – 27 Feb 2014 and Interphex New York 18 – 20 March 2014.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Company News Release,
Click here